Drug Sponsors

DOD awards Luminex $11.6M to develop biothreat detection tech

Friday, August 10, 2012 02:42 PM

Luminex, a developer and manufacturer of biological testing technologies based in Austin, Texas, has been awarded a contract worth up to $11.6 million over three and a half years by the Department of Defense (DOD).

More... »

Aquavit, Green Cross sign strategic collaboration MOU on IBX-001

Friday, August 10, 2012 12:07 PM

Aquavit Pharmaceuticals, a multi-specialty healthcare company of New York, and Green Cross, a South Korean biotechnology company, signed a Memorandum of Understanding (MOU) towards establishing their strategic collaboration surrounding the development and commercialization of Aquavit's IBX-001 in Asia.

More... »

Platinum-Montaur finances $20M to Echo Therapeutics

Friday, August 10, 2012 11:29 AM

Platinum-Montaur Life Sciences has agreed to provide Echo Therapeutics, a transdermal medical device company, a credit facility of up to $20 million.

More... »

Accu-Break, Alembic enter into product development and license agreement

Friday, August 10, 2012 11:02 AM

India-based Accu-Break Pharmaceuticals (ABP) has entered into a development and license agreement with Alembic Pharmaceuticals of Plantation, Fla., to develop new brand products that will use ABP’s innovative Accu-Break tablet technologies.

More... »

Nodality, Pfizer form multi-year collaboration on autoimmune disease

Thursday, August 9, 2012 02:16 PM

Nodality, a San Francisco-based personalized medicine biotech, has formed a strategic collaboration to provide proprietary single cell network profiling (SCNP) technology as a tool for the development of Pfizer compounds.

More... »

Bioventus selects The Netherlands for international headquarters

Thursday, August 9, 2012 10:15 AM

Bioventus, a Durham, N.C.-based company focusing on active orthopaedic healing, has decided to establish its international headquarters in Hoofddorp, The Netherlands, about 12 miles outside of Amsterdam.

More... »

Synthetic Biologics, Intrexon collaborate on infectious diseases

Wednesday, August 8, 2012 01:55 PM

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic biologics and innovative medicines for unmet medical needs, and Intrexon, a Germantown, Md.-based synthetic biology company that provides control over cellular function, have entered into a second worldwide exclusive channel collaboration through which Synthetic Biologics intends to develop and commercialize a series of monoclonal antibody (mAb) therapies for the treatment of certain infectious diseases not adequately addressed by existing therapies.

More... »

Amneal to invest $120M to grow U.S. operations, create 500 jobs

Wednesday, August 8, 2012 11:21 AM

Amneal Pharmaceuticals, a manufacturer of generic pharmaceuticals based in Hauppauge, N.Y., is investing $120 million in physical plant capital expenditures from 2012-2014 to significantly grow its operations at three of its six current U.S. R&D, manufacturing and distribution facilities.

More... »

EMD Millipore inks exclusive agreement with Julphar Diabetes for insulin

Wednesday, August 8, 2012 11:02 AM

EMD Millipore, the life science division of Merck KGaA, has announced an exclusive agreement to sell recombinant human insulin manufactured by Julphar Diabetes, a pharmaceutical production company based in the United Arab Emirates.

More... »

DKSH divests contract manufacturing plant OLIC to Fuji Pharma

Wednesday, August 8, 2012 10:47 AM

DKSH, a market expansion services provider with a focus on Asia, has agreed to divest OLIC, a contract manufacturing operation of pharmaceutical products in Thailand, to Fuji Pharma of Japan. The transaction is subject to customary closing conditions.

More... »